LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Pfizer

Pfizer

Suletud

Sektor Tervishoid

28.56 0.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.35

Max

28.56

Põhinäitajad
By Trading Economics
Sissetulek	-3.1B 41M
Müük	-1.6B 13B
P/E Sektori keskmine	15.73 103.001
Aktsiakasum	0.6
Kasumimarginaal	0.308
Töötajad	88,000
EBITDA	-3.5B 2.4B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+14.74 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. okt 2024
Järgmine dividendimakse kuupäev	2. dets 2024
Järgmine aktsia dividendi kuupäev (ex-date)	7. nov 2024

Turustatistika
By TradingEconomics
Turukapital	164B
Eelmine avamishind	28.24
Eelmine sulgemishind	28.56

Uudiste sentiment

By Acuity

54%

46%

292 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

28.56 / 28.77 Toetus ja vastupanu

Pfizer Graafik

Seotud uudised

3. sept 2024, 10:28 UTC

Tulu

Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

3. sept 2024, 17:22 UTC

Peamised uudised

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

3. sept 2024, 10:31 UTC

Market Talk

Valneva Shares Gain on Positive Vaccine News -- Market Talk

23. aug 2024, 18:38 UTC

Peamised uudised

The U.S. Is Bringing Back Free Covid Tests This Fall -- Barrons.com

19. aug 2024, 09:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Pfizer Is Staking Its Turnaround on Cancer Drugs -- WSJ

8. aug 2024, 10:30 UTC

Peamised uudised

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It -2-

1. aug 2024, 15:56 UTC

Tulu

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

1. aug 2024, 10:30 UTC

Peamised uudised

Moderna Cuts Revenue Guidance Amid Steeper Competition -- Barrons.com

30. juuli 2024, 17:18 UTC

Tulu

Pfizer Raises Outlook Amid Strong Demand for Non-Covid Products -- WSJ

30. juuli 2024, 15:53 UTC

Tulu

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30. juuli 2024, 15:52 UTC

Peamised uudised

Heard on the Street: Pfizer Finally Gets Past Covid -- WSJ

30. juuli 2024, 11:37 UTC

Tulu

Pfizer Stock Rises After Guidance Hike, Earnings Beat. -- Barrons.com

30. juuli 2024, 11:18 UTC

Peamised uudised

Tulu

Pfizer Stock Rises After Drug Maker Raises Outlook -- WSJ

30. juuli 2024, 11:12 UTC

Tulu

Pfizer Stock Rises On Earnings Beat, Raised Outlook -- IBD

30. juuli 2024, 11:01 UTC

Tulu

Pfizer's Stock Pops After Earnings Beat As Company Raises Guidance And Unveils Cost Cuts -- MarketWatch

30. juuli 2024, 10:50 UTC

Tulu

Pfizer: Current Guidance Doesn't Anticipate Any Share Repurchases in 2024 >PFE

30. juuli 2024, 10:49 UTC

Tulu

Pfizer Sees 2024 Adjusted R&D Expenses $11B-$12B >PFE

30. juuli 2024, 10:49 UTC

Tulu

Pfizer Had Seen 2024 Adjusted EPS $2.15-$2.35 >PFE

30. juuli 2024, 10:48 UTC

Tulu

Pfizer Now Sees 2024 Operational Rev Growth of 9%-11%; Had Seen 8%-10% >PFE

30. juuli 2024, 10:47 UTC

Tulu

Pfizer Raises 2024 View To Adj EPS $2.45-Adj EPS $2.65 >PFE

30. juuli 2024, 10:47 UTC

Tulu

Pfizer Raises 2024 View To Rev $59.5B-$62.5B >PFE

30. juuli 2024, 10:47 UTC

Tulu

Pfizer 2Q Biopharma Revenue $12.99B, Up 2% >PFE

30. juuli 2024, 10:46 UTC

Tulu

Pfizer: On Track for at Least $4B Net Cost Savings by End 2024 From Cost-Realignment Program >PFE

30. juuli 2024, 10:45 UTC

Tulu

Pfizer Posts $1.3B 2Q Costs for Manufacturing Optimization Program >PFE

30. juuli 2024, 10:45 UTC

Tulu

Pfizer Raises 2024 Guidance >PFE

30. juuli 2024, 10:45 UTC

Tulu

Pfizer 2Q Rev $13.3B >PFE

30. juuli 2024, 10:45 UTC

Tulu

Pfizer 2Q EPS 1c >PFE

30. juuli 2024, 10:45 UTC

Tulu

Pfizer 2Q Adj EPS 60c >PFE

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

14.74% tõus

12 kuu keskmine prognoos

Keskmine 32.77 USD 14.74%

Kõrge 45 USD

Madal 27 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi Pfizer aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.56 / 28.77Toetus ja vastupanu

Bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

292 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pfizer

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.